Trial of multi-cancer blood test among 142,000 NHS patients fails to meet main aim
A major NHS trial found Galleri did not significantly cut late-stage cancer diagnoses overall, though some secondary results looked promising.
Intelligence analysis by GPT-5.4 Mini
The first randomised trial of a multi-cancer early detection blood test in the NHS did not meet its main goal: reducing advanced cancer diagnoses. Supporters point to encouraging secondary signals, but critics say the core result does not justify rollout at population scale.
Scientists tested a blood test called Galleri in a very large group of people who did not have cancer signs. The idea was simple: find hidden cancers sooner, before they get harder to treat.
The test did not achieve its main goal. It did not clearly lower the number of cancers found at late stages when compared with regular screening alone.
It is like checking a school hallway with a new flashlight. The flashlight may spot some things earlier, but if it does not clearly help find the biggest problems sooner, people will want more proof before buying lots of them.
Analysis
What the trial tested
The study enrolled 142,942 symptom-free people aged 50 to 77 in the UK. Everyone had standard recommended cancer screening, and half also had the Galleri blood test once a year for three years. If Galleri was positive, patients were sent for diagnostic follow-up.
Main result
Researchers were trying to show that adding Galleri would reduce stage 3 and stage 4 cancers across a predefined group of 12 cancers. That primary endpoint was not met. In plain terms, the blood test did not produce a statistically significant drop in late-stage cancer diagnoses overall compared with standard screening alone.
How supporters framed it
Grail said it was encouraged by other findings from the trial, including data on stage 4 cancers alone, which it said fell by 14%. The company described Galleri as a possible major step forward in cancer detection. ASCO’s chief medical officer, Julie Gralow, said the study showed some encouraging trends toward tumour downstaging, but not a statistical reduction in late-stage cancers by the trial’s main measure.
Skeptical reaction
Experts not involved in the trial were more cautious. Richard Houlston of the Institute of Cancer Research said the results had been presented more positively than they justified, arguing that the primary endpoint was the key issue. He said the secondary findings remain uncertain and should be interpreted carefully.
What happens next
The article says mortality results will be available in a couple of years. Those data may matter more than stage shifts if the question is whether the test actually helps people live longer. For now, the study weakens the case for rolling Galleri out at population scale in the NHS.
Key points
- The NHS trial included 142,942 people aged 50 to 77 with no cancer symptoms.
- Galleri did not significantly reduce late-stage cancer diagnoses overall, which was the trial’s main aim.
- The company highlighted secondary findings, including a reported 14% drop in stage 4 cancers alone.
- Independent experts said the primary endpoint was not met and urged caution.
- Researchers say mortality results should arrive in a couple of years.
